Krebsforum Lazarus

Bitte loggen sie sich ein oder registrieren sie sich.

Einloggen mit Benutzername, Passwort und Sitzungslänge
Erweiterte Suche  

Autor Thema: Virus injection could kill brain tumour cells  (Gelesen 1340 mal)

Glückspilz

  • Globaler Moderator
  • Held Mitglied
  • *****
  • Beiträge: 848
Virus injection could kill brain tumour cells
« am: 14. Februar 2014, 16:44:23 »

http://www.bbc.co.uk/news/health-26188765

[*QUOTE*]
------------------------------------------------------------------------------------
Virus injection could kill brain tumour cells
1 hour ago

Injecting brain tumours with a virus could kill cancer cells but leave healthy cells unharmed, researchers suggest.

Scientists at the University of Leeds have been given a £3 million grant to research the method over five years.

Because the treatment is non-toxic, they hope it could be used on elderly patients and children.

Neuro-oncologist Susan Short, who is leading the project, told BBC Radio 5 live's Breakfast: "We're hoping that before the end of the year we can offer the treatment within clinical studies."
------------------------------------------------------------------------------------
[*/QUOTE*]



http://www.ecmcnetwork.org.uk/news-events/news/LEEDS2609

[*QUOTE*]
------------------------------------------------------------------------------------
World-first trial tests whether anti-cancer virus can be delivered direct to cancer cells

Leeds ECMC has started a study to examine if therapeutic, systemically delivered viruses can cross the blood brain barrier to access brain tumours.

The study follows the centre's REO13 trial which was a Phase 1B University of Leeds-sponsored translational, biological endpoint study, the first of its kind worldwide generating human data to inform the development of clinical trials (Adair et al, Science Translational Medicine 20012). Professor Melcher, who is leading the current trial together with Professor Susan Short explained:  "The question in REO13  was, can a virus, after injection into the circulation, access tumours in patients? It was really the study design and the planned biological endpoint that others had never looked at."

The study found that an anti-cancer 'oncolytic virus', reovirus, was protected from neutralizing antibodies by cells in the blood, and was specifically delivered to colorectal cancer metastatic to the liver.
 Since July this year, the centre has been running a similar study (REO13 BRAIN) in brain tumours, giving intravenous reovirus prior to resection of recurrent glioblastoma multiforme or brain metastases.  Professor Melcher said: "This new trial will address the question of whether therapeutic, systemically delivered viruses can cross the blood brain barrier to access brain tumours in patients. We have also taken our clinical data back to the laboratory, and shown that in mice combination of systemic reovirus with GMCSF (which boosts virus immune carrier cell numbers and function in the circulation), significantly enhances therapy.  This result will form the basis of a future trial adding GMCSF to reovirus therapy in melanoma and ovarian cancer patients, illustrating our strategy to deliver truly iterative research, taking our research from laboratory to clinic and back again."
------------------------------------------------------------------------------------
[*/QUOTE*]



http://www.youtube.com/watch?v=oFj09yR1974

[*QUOTE*]
------------------------------------------------------------------------------------
BrainTumourCharity·

Targeting brain tumours with 'cancer-killing' viruses

Published on 13 Feb 2014

Professor Susan Short talks about her new ground-breaking research programme aiming to harness the power of certain viruses that can kill high grade glioma brain tumour cells without harming healthy ones.

The Brain Tumour Charity are co-funding the £3million study at the University of Leeds with a £1.5million grant.
------------------------------------------------------------------------------------
[*/QUOTE*]



http://medhealth.leeds.ac.uk/info/950/oncology_and_clinical_research_laboratory

[*QUOTE*]
------------------------------------------------------------------------------------
Leeds Institute of Cancer & Pathology

You are here: Faculty of Medicine and Health> Leeds Institute of Cancer & Pathology> Research> Oncology and Clinical Research (Laboratory)
Oncology and Clinical Research (Laboratory)

Led by Professor Alan Melcher

The laboratory activity of the Section of Oncology and Clinical Research is focused on both basic and translational research, with  particular interests in viruses and cancer, the interaction between the host immune system and tumours, and neuro-oncology. There is also major activity in the areas of renal cancer, biomarkers, therapeutic target discovery, proteomics and angiogenesis.

These areas overlap across a range of specific research projects, for example: hepatitis C virus as a causative agent in liver cancer; using oncolytic viruses to treat cancer and activate natural killer immune cells; cancer stem cells and the tumour microenvironment within brain tumours; targeted radiotherapy as part of combination treatments for cancers within the brain.

In all our research we use a range of model systems, including tumour tissue from patients, to ensure our findings have the greatest relevance possible to inform new treatment strategies in the clinic.

Groups

Targeted and Biological Therapies Research Group
Group Leader: Professor Alan Melcher

Clinical and Biomedical Proteomics Research Group
Group Leader: Professor Rosamonde Banks

Antivirals & Viral Oncology Research Group
Group Leader: Dr Stephen Griffin

Molecular and Cellular Immunology Research Group
Group Leader: Dr Graham Cook

Translational Neuro-Oncology
Group Leader: Professor Susan Short

Tumour Angiogenesis Research Group
Group Leader: Dr Georgia Mavria

Stem Cells and Brain Tumour Research Group
Group Leader: Dr Heiko Wurdak


Translational Neuro-Oncology Group
Group Leader: Professor Susan Short 

The ‘Translational Neuro-Oncology’ group works on new approaches to treating gliomas.  We focus on understanding glioma biology and the potential for early clinical translation, particularly through application of agents that target glioma cell migration and cell survival after radiotherapy.
-  Research Areas

Radiation biology applied to glioma and DNA repair in glioma cells as a target, including homologous recombination and mis-match repair pathways in glioma cells with stem-like properties.

Response of glioma cells to treatment, association with stem cell phenotype and mechanisms of cell death

Application of novel radiotherapy technology in CNS tumours, including application of image-guided pre-clinical radiotherapy and clinical studies of IMRT in good prognosis patient groups.

Role of micro-RNA in defining adult and paediatric glioma biology, particularly at transition from low to high-grade tumours.

Means of targeting glioma migration using small molecule inhibitors including those targeting GSK3 
-  People

Dr Tim Brend, Post-doctoral Scientist
Dr Henry King, Research Technician
Dr Anke Bruning-Richardson, Post-doctoral Scientist
Dr Jane Levesley, Post-doctoral Scientist
Dr Lynette Steele, Research Technician
Dr Marjorie Boissinot, Post-doctoral Scientist
Josie Hayes, PhD Fellow
-  Publications

J Maclean, N Fersht, F Bremner, S C Short. (2013). Meningioma causing visual impairment; outcomes and toxicity after intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 85(4).e179-86.

S C Short, S Giampieri, M Worku, M German, G Sioftanos, S Bourne and C Martindale (2011). Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumour derived cells. Neuro-Oncology.13 (5) 487-499.

Chalmers, A.J, Lovegrove, N., Rust, E, Martindale, C and Short, S.C.(2009). Cytotoxicity of radiation and temozolomide in glioma cells is additive and schedule dependent. Int J Radiat Oncol Biol Phys. Dec 1(75).
-  Funding

Therapeutic potential of targeting DNA repair in CNS tumours. CRUK Senior Fellowship. Personal funding. 2009-2015.

Clinical and Biological Optimisation of IMRT in meningioma. UCL/UCLH Comprehensive Biomedical Research Centre Project Grant.  2009-2013 . PI S Short.

Hydroxychloroquine and short course radiotherapy for elderly patients with glioblastoma. CTAAC project grant. Awarded 2011-2014.  PI S Short.

FP7–health-2012-innovation. SME targeted collaborative project. INSERT "Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy”. Awarded 2012-2015. Co-ordinator C Fiorini. WP6 co-ordinator S Short.

MICA: GSK-3 as a multifunctional target for glioblastoma treatment; hitting multiple tumour hallmarks with a single drug. MRC project grant. Awarded 2012 -2015. PI S Short.

Investigating GSK3 inhibition in glioma. PPR Foundation project grant. 2012-2015. PI S Short.

Micro-RNAs in glioma migration and proliferation. YCR project grant. 2011-2014. PI S Short.

YCR PhD studentship. 2012-2015. PI S Short.
-  Studentships

Leeds Cancer Research UK Centre Clinical Research Fellowships (http://www.cancercentre.leeds.ac.uk/for-researchers/training/clinical-research-fellowships/)

Leeds Cancer Research UK Centre PhD Studentships (http://www.cancercentre.leeds.ac.uk/for-researchers/training/phd-studentships/)
------------------------------------------------------------------------------------
[*/QUOTE*]
« Letzte Änderung: 14. Februar 2014, 16:53:51 von Glückspilz »
Gespeichert
Würde ich von Licht leben,
müßte ich grün sein.